Israeli Startup X-tosis Pushes Experimental Parkinson's and Alzheimer's Drug Toward Human Trials
Built on Ben-Gurion University research into a mitochondrial protein, Gainesville-based X-tosis is seeking investors to launch a first human trial of a drug it hopes can slow Parkinson's and Alzheimer's disease.
By Luca Fernandez ·

Ofer Shina is 38 and carries a gene that brings on Alzheimer's disease early. His father began losing his memory at 40, and an uncle developed the same symptoms; genetic testing traced the cause to an aggressive mutation in a gene called PSEN1 found in about half of his father's side of the family. Shina was tested after his father died. "For me, knowing is more important," he said. "Putting a light on it is better."
A product manager with 13 years in tech and no biology training, Shina taught himself to read a scientific paper every day and says he examined more than 200 possible approaches and thousands of papers. Most targeted amyloid, the protein behind hundreds of failed Alzheimer's trials. Then he found the work of Prof. Varda Shoshan-Barmatz at Ben-Gurion University of the Negev.
Shoshan-Barmatz has studied VDAC1, a protein in the outer wall of the mitochondria, for about 25 years. "It is the gate," she said. Her central finding is that cells under stress make too much of the protein, and the extra units link into pores that release molecules triggering cell death and inflammation. Her lab and collaborators have reported elevated VDAC1 levels in models and tissue samples of Alzheimer's, Parkinson's, ALS and Type 2 diabetes. Screening thousands of molecules for ones that stop the pores from forming, her lab produced a candidate, VBIT-4.
In a 2019 paper in the journal Science, written with US National Institutes of Health researchers, her team showed the pores let genetic material escape from mitochondria and set off inflammation, and that VBIT-4 blocked that and reduced lupus-like disease in mice. A 2022 study in Translational Neurodegeneration found the drug prevented memory loss, learning loss and neuronal death in mice predisposed to Alzheimer's, while amyloid levels fell only about 10%. She argues that amyloid triggers VDAC1 overproduction rather than causing the disease directly, and estimates an amyloid-only drug would have to remove 95% or more of it.
Shina is co-founder and chief operating officer of X-tosis, Inc., a Gainesville, Florida, biotech built on her research that renamed the drug XTS001. The Michael J. Fox Foundation for Parkinson's Research awarded a $2.74 million grant, announced in June, to push it toward human trials, aiming first at Parkinson's in the hope of slowing the disease itself, and later at Alzheimer's. It is being developed as an oral treatment, unlike the newest approved Alzheimer's drugs, antibodies given by infusion or injection that carry a risk of brain swelling and bleeding.
A first company built on the molecules closed after the Oct. 7, 2023, attack, when its investor pulled out, and BGN Technologies, the university's commercial arm, took the license back. Shoshan-Barmatz and Dr. Galit Mazooz-Perlmuter, BGN's senior vice president for biopharma business development, both tried to send Shina away. "I pushed him away for a year, and he kept knocking on my door," Mazooz-Perlmuter said. "He had the vision." It is the only company BGN has set up in the United States.
Chief executive Erin Henderson said Israel has strong research but local investors rarely fund beyond seed rounds, and the war kept scientists from the conferences where investors learn about a lab's work. Shina cited speed and money: drug development runs through US regulators, and most of the field's capital is in America. The company has no lab of its own, contracts research in India, the US, Europe and Shoshan-Barmatz's lab, and was assembled during the war in meetings interrupted by missile sirens.
No approved drug has been shown to slow Parkinson's. Rival mitochondrial approaches are advancing too: Vincere Biosciences won a $5 million grant from the same foundation program in 2025 and was still in animal safety testing in June, and a trial in the Netherlands is testing another drug in patients.
Henderson said the company is in active diligence with multiple investors. If the money comes, she expects a first human trial in 12 to 18 months, most likely in the US, Britain or Australia, where early trials cost about 30% less. Phase 1 would test safety in 25 to 60 healthy volunteers; a final large-scale trial can cost close to $300 million. Approval is at best about six years away, and no one knows whether the drug will come in time for Shina. "Everybody is warning me all the time not to use 'cure,'" he said.






